{"0LW.F": {"short_name": "NEOVACS NOM.  EO-,05", "long_name": "Neovacs S.A.", "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "1F6.F": {"short_name": "FERMENTALG  EO -,04", "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme", "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Libourne"}, "2E4.F": {"short_name": "ERYTECH PHARMA SA  EO-,10", "long_name": "ERYTECH Pharma S.A.", "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lyon"}, "2E4A.F": {"short_name": "ERYTECH PHARMA SP.ADR-,10", "long_name": "ERYTECH Pharma S.A.", "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lyon"}, "2X1.F": {"short_name": "ABIVAX SA  EO -,01", "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "3MM.F": {"short_name": "ADVICENNE (PROM.) EO-,20", "long_name": "Advicenne S.A.", "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "5D8.F": {"short_name": "DEINOVE  EO-,40", "long_name": "Deinove SA", "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Grabels"}, "5NR.F": {"short_name": "NANOBIOTIX INH.  EO-,03", "long_name": "Nanobiotix S.A.", "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "609.F": {"short_name": "ABIONYX PHARMA SA  EO-,05", "long_name": "ABIONYX Pharma SA", "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Labege"}, "609.SG": {"short_name": "ABIONYX PHARMA", "long_name": "ABIONYX Pharma SA", "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "France", "city": "Labege"}, "7PO.F": {"short_name": "POXEL S.A.  EO -,02", "long_name": "Poxel S.A.", "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lyon"}, "A89.F": {"short_name": "ADOCIA SAS  EO -,10", "long_name": "Adocia SA", "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lyon"}, "AAVXF": {"short_name": "ABIVAX", "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Paris"}, "ABNX.PA": {"short_name": "ABIONYX PHARMA", "long_name": "ABIONYX Pharma SA", "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Labege"}, "ABVX.PA": {"short_name": "ABIVAX", "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ADOC.PA": {"short_name": "ADOCIA", "long_name": "Adocia SA", "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lyon"}, "ADOCY": {"short_name": "ADOCIA", "long_name": "Adocia SA", "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Lyon"}, "ADVIC.PA": {"short_name": "ADVICENNE", "long_name": "Advicenne S.A.", "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALBPS.PA": {"short_name": "BIOPHYTIS", "long_name": "Biophytis SA", "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALCLS.PA": {"short_name": "CELLECTIS", "long_name": "Cellectis S.A.", "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALDEI.PA": {"short_name": "DEINOVE", "long_name": "Deinove SA", "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Grabels"}, "ALGEN.PA": {"short_name": "GENOWAY", "long_name": "genOway Soci\u00e9t\u00e9 anonyme", "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lyon"}, "ALHYG.PA": {"short_name": "HYBRIGENICS", "long_name": "Hybrigenics Soci\u00e9t\u00e9 Anonyme", "summary": "Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme comprises biopharmaceutical company. Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme is located in France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "None"}, "ALINT.PA": {"short_name": "INTEGRAGEN", "long_name": "IntegraGen SA", "summary": "As of October 21, 2020, IntegraGen SA operates as a subsidiary of OncoDNA SA.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Evry"}, "ALNEV.PA": {"short_name": "NEOVACS", "long_name": "Neovacs S.A.", "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALONC.PA": {"short_name": "ONCODESIGN", "long_name": "Oncodesign Soci\u00e9t\u00e9 Anonyme", "summary": "Oncodesign Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Dijon"}, "ALONX.PA": {"short_name": "ONXEO", "long_name": "Onxeo SA", "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALPAT.PA": {"short_name": "PLANT ADVANCED", "long_name": "Plant Advanced Technologies SA", "summary": "Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. The company's technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. Plant Advanced Technologies SA was founded in 2005 and is headquartered in Vand\u00c2\u009cuvre-l\u00c3\u00a8s-Nancy, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Vand\u00c5\u0093uvre-l\u00c3\u00a8s-Nancy"}, "ALPHA.PA": {"short_name": "PHARNEXT", "long_name": "Pharnext SA", "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Issy-les-Moulineaux"}, "ALQGC.PA": {"short_name": "QUANTUM GENOMICS", "long_name": "Quantum Genomics Soci\u00e9t\u00e9 Anonyme", "summary": "Quantum Genomics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug for the treatment of hypertension and heart failure, as well as acts on the inhibition of Aminopeptidase A in the brain. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company is based in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "ALSEN.PA": {"short_name": "SENSORION", "long_name": "Sensorion SA", "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Montpellier"}, "ALTHX.PA": {"short_name": "THERANEXUS", "long_name": "Theranexus Soci\u00e9t\u00e9 Anonyme", "summary": "Theranexus soci\u00c3\u00a9t\u00c3\u00a9 anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lyon"}, "ALVAL.PA": {"short_name": "VALBIOTIS", "long_name": "Valbiotis SA", "summary": "Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. The company also develops VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product for providing nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. In addition, the company's products under clinical development comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VAL-070, which reduces lipid dysfunctions cholesterol, a risk factor for cardiovascular disease. Valbiotis SA was founded in 2014 and is based in P\u00c3\u00a9rigny, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "P\u00c3\u00a9rigny"}, "AYJ.F": {"short_name": "VALNEVA SE  EO -,15", "long_name": "Valneva SE", "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Nantes"}, "C4X.F": {"short_name": "ONXEO S.A. AC.PORT.EO-,25", "long_name": "Onxeo SA", "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "CLLS": {"short_name": "Cellectis S.A.", "long_name": "Cellectis S.A.", "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Paris"}, "CMVLF": {"short_name": "CELLECTIS", "long_name": "Cellectis S.A.", "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Paris"}, "COX.PA": {"short_name": "NICOX", "long_name": "Nicox S.A.", "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Valbonne"}, "DBV.F": {"short_name": "DBV TECHNOLOGIES  EO -,10", "long_name": "DBV Technologies S.A.", "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Montrouge"}, "DBV.PA": {"short_name": "DBV TECHNOLOGIES", "long_name": "DBV Technologies S.A.", "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Montrouge"}, "DBVA.F": {"short_name": "DBV TECH.SP.ADR 1/2 EO-10", "long_name": "DBV Technologies S.A.", "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Montrouge"}, "DBVT": {"short_name": "DBV Technologies S.A.", "long_name": "DBV Technologies S.A.", "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Montrouge"}, "ERYP": {"short_name": "Erytech Pharma S.A.", "long_name": "ERYTECH Pharma S.A.", "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Lyon"}, "ERYP.PA": {"short_name": "ERYTECH PHARMA", "long_name": "ERYTECH Pharma S.A.", "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lyon"}, "FALG.PA": {"short_name": "FERMENTALG", "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme", "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Libourne"}, "G061.F": {"short_name": "GENKYOTEX S.A. EO 1,-", "long_name": "Genkyotex SA", "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lab\u00c3\u00a8ge"}, "G49N.F": {"short_name": "GENSIGHT BIOLOG. EO -,025", "long_name": "GenSight Biologics S.A.", "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "GKTX.PA": {"short_name": "GENKYOTEX", "long_name": "Genkyotex SA", "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lab\u00c3\u00a8ge"}, "GNFT": {"short_name": "GENFIT S.A.", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Loos"}, "GNFT.PA": {"short_name": "GENFIT", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Loos"}, "GNFTF": {"short_name": "GENFIT", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Loos"}, "IDD.F": {"short_name": "INNATE PHARMA  EO -,05", "long_name": "Innate Pharma S.A.", "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Marseille"}, "IDDA.MU": {"short_name": "INNATE PHARMA SP.ADR/1", "long_name": "Innate Pharma S.A.", "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MUN", "market": "dr_market", "country": "France", "city": "Marseille"}, "INRLF": {"short_name": "VALNEVA SE", "long_name": "Valneva SE", "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Nantes"}, "IPH.PA": {"short_name": "INNATE PHARMA", "long_name": "Innate Pharma S.A.", "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Marseille"}, "IPHA": {"short_name": "Innate Pharma S.A.", "long_name": "Innate Pharma S.A.", "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Marseille"}, "IPHYF": {"short_name": "INNATE PHARMA", "long_name": "Innate Pharma S.A.", "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Marseille"}, "IVA": {"short_name": "Inventiva S.A. - American Depos", "long_name": "Inventiva S.A.", "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Daix"}, "IVA.PA": {"short_name": "INVENTIVA", "long_name": "Inventiva S.A.", "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Daix"}, "JEH.F": {"short_name": "GENOWAY S.A. INH.  EO-,60", "long_name": "genOway S.A.", "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Lyon"}, "LYS.PA": {"short_name": "LYSOGENE", "long_name": "Lysogene S.A.", "summary": "Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Neuilly-sur-Seine"}, "MDCLF": {"short_name": "MEDINCELL SA", "long_name": "MedinCell S.A.", "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Jacou"}, "MEB.F": {"short_name": "MEDINCELL S.A.  EO-,01", "long_name": "MedinCell S.A.", "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Jacou"}, "MEDCL.PA": {"short_name": "MEDINCELL", "long_name": "MedinCell S.A.", "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Jacou"}, "NANO.PA": {"short_name": "NANOBIOTIX", "long_name": "Nanobiotix S.A.", "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "NBTX": {"short_name": "Nanobiotix S.A.", "long_name": "Nanobiotix S.A.", "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "France", "city": "Paris"}, "NICXF": {"short_name": "NICOX SA", "long_name": "Nicox S.A.", "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Valbonne"}, "NXOA.F": {"short_name": "NICOX SA INH.  EO 1", "long_name": "Nicox S.A.", "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Valbonne"}, "ONXEO.CO": {"short_name": "Onxeo SA", "long_name": "Onxeo SA", "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.", "currency": "DKK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "CPH", "market": "dk_market", "country": "France", "city": "Paris"}, "P0X.SG": {"short_name": "Pharnext Actions Nom. EO-,01", "long_name": "Pharnext SA", "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "France", "city": "Issy-les-Moulineaux"}, "PNEXF": {"short_name": "PHARNEXT", "long_name": "Pharnext SA", "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Issy-les-Moulineaux"}, "POXEL.PA": {"short_name": "POXEL", "long_name": "Poxel S.A.", "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Lyon"}, "RFM.SG": {"short_name": "Sensorion S.A. Actions au Porte", "long_name": "Sensorion SA", "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "France", "city": "Montpellier"}, "SIGHT.PA": {"short_name": "GENSIGHT BIOLOGICS", "long_name": "GenSight Biologics S.A.", "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Paris"}, "TGNA.F": {"short_name": "TRANSGENE SA  EO 0,50", "long_name": "Transgene SA", "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Illkirch-Graffenstaden"}, "TNG.PA": {"short_name": "TRANSGENE", "long_name": "Transgene SA", "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Illkirch-Graffenstaden"}, "TRGNF": {"short_name": "TRANSGENE", "long_name": "Transgene SA", "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "France", "city": "Illkirch-Graffenstaden"}, "VLA.PA": {"short_name": "VALNEVA", "long_name": "Valneva SE", "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PAR", "market": "fr_market", "country": "France", "city": "Nantes"}, "XUP.F": {"short_name": "GENFIT S.A.  EO -,25", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Loos"}, "XUP.SG": {"short_name": "Genfit S.A. Actions au Port. EO", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "France", "city": "Loos"}, "XUPB.MU": {"short_name": "GENFIT S.A.  ADR/1 EO-,25", "long_name": "Genfit SA", "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MUN", "market": "dr_market", "country": "France", "city": "Loos"}, "ZVA.F": {"short_name": "CELLECTIS NOM.  EO-,05", "long_name": "Cellectis S.A.", "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}, "ZVAA.F": {"short_name": "CELLECTIS SP.ADR 1 EO-,05", "long_name": "Cellectis S.A.", "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "France", "city": "Paris"}}